ClinicalTrials.gg
RecruitingNCT07466212QoLIDiaUpdated Oct 22, 2026

QoLIDia: Quality of Life in Cancer Patients With Diabetes During Immunotherapy

An observational study in Cancer and Type 2 Diabetes, sponsored by Odense University Hospital. Recruiting at 4 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Odense University Hospital · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 22, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
920
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to see how type 2 diabetes affects quality of life in cancer patients receiving immunotherapy. We want to know if patients with diabetes have a greater decline in quality of life over six months compared to those without. The main question we aim to answer is:

- How does quality of life change over six months in patients with versus without diabetes?

Participants will complete quality-of-life surveys at the start, then at 3 and 6 months. This will help us see if diabetes adds extra challenges during cancer treatment

Read the detailed description

Immune checkpoint inhibitors (ICIs) have transformed the management of multiple solid malignancies by improving survival and enabling durable disease control. By targeting inhibitory immune checkpoints such as PD-1, PD-L1, and CTLA-4, these therapies enhance anti-tumour immune responses. However, immune activation may also result in immune-related adverse events (irAEs), which can affect multiple organ systems and range from mild to life-threatening. As survival improves, long-term and chronic toxicities are increasingly recognised, highlighting the importance of patient-centred outcomes such as health-related quality of life (HRQoL).

Diabetes mellitus (DM) is a common comorbidity among patients with cancer and is associated with increased symptom burden, functional impairment, and reduced HRQoL. Type 2 diabetes (T2D) has also been associated with adverse cancer outcomes and may influence both the effectiveness and toxicity profile of systemic anticancer therapy, including ICIs. In addition, ICIs can induce immune-related diabetes mellitus (ir-DM), a rare but clinically significant form of new-onset insulin-dependent diabetes requiring lifelong insulin treatment. Despite its clinical relevance, the interaction between pre-existing diabetes, ICI therapy, and longitudinal HRQoL remains insufficiently characterised.

Although HRQoL is generally reported to remain stable during ICI therapy in unselected cancer populations, it is unknown whether similar patterns are observed in patients with pre-existing DM or in those who develop ir-DM during treatment. Given the metabolic, functional, and psychosocial burden associated with diabetes, this patient group may be particularly vulnerable to deterioration in HRQoL during immunotherapy.

The primary aim of this study is to compare longitudinal changes in HRQoL between patients with T2D and non-diabetic patients from baseline to 3 and 6 months after initiation of ICI therapy. The primary hypothesis is that patients with T2D will experience a greater decline in HRQoL over the first six months of treatment compared with non-diabetic patients.

This is a prospective, multicentre cohort study of adult cancer patients initiating ICI therapy. Data will be collected prospectively using a secure electronic case report form across participating centres.

At baseline, demographic characteristics, cancer type and stage, treatment intent and planned ICI regimen, diabetes status (no diabetes, type 1 diabetes, or type 2 diabetes), diabetes treatment status, performance status, and baseline patient-reported outcomes will be recorded.

During follow-up, data will be collected on ICI exposure, treatment discontinuation and reasons for discontinuation, immune-related adverse events, hospitalisations, disease progression, survival status, and the occurrence of immune-related diabetes mellitus.

Patient-reported outcomes will be assessed using the EORTC QLQ-C30 and EQ-5D-5L questionnaires in all participants, and the PAID questionnaire in participants with diabetes. Assessments will be performed at baseline and at 3 and 6 months after treatment initiation.

Immune-related diabetes mellitus will be defined as new-onset insulin-dependent diabetes occurring after initiation of ICI therapy and consistent with marked beta-cell failure, classified according to established international clinical recommendations.

This study will provide prospective real-world data on HRQoL trajectories and survival among cancer patients with and without diabetes receiving ICI therapy, and will estimate the incidence and clinical characteristics of immune-related diabetes mellitus in a nationwide setting.

02

Conditions studied

  • Cancer
  • Type 2 Diabetes

Keywords

  • Type 2 diabetes
  • Cancer
  • Immunotherapy
  • Quality of life
  • Patient-reported outcomes
  • Real-world study
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 920 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Odense University Hospital is the lead sponsor of 480 studies on the registry; 111 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with solid malignancies initiating immune checkpoint inhibitor therapy in routine clinical practice, with and without pre-existing type 2 diabetes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • confirmed solid malignant tumor.
  • Planned treatment with ICI monotherapy or dual-ICI combination therapy (, adjuvant, or settings).
  • Previous systemic anticancer therapy other than ICI is allowed.
  • Ability and willingness to provide written and to complete HRQoL questionnaires.
  • Sufficient Danish language proficiency to read, and complete study questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Previous ICI treatment within 6 months.
  • Concurrent systemic anticancer therapy other than ICI.
  • Declines or does not provide .
  • Cognitive or physical impairment preventing valid consent or completion of patient-reported outcomes.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
920 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • Patients with type 2 diabetes

    The patients have cancer and receive immunotherapy

  • Patients without diabetes

    The patients have cancer and receive immunotherapy

06

What researchers measure

Primary outcomes

  1. Change in EORTC QLQ-C30 Global Health Status score

    Change in health-related quality of life measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status scale. Scores range from 0 to 100, with higher scores indicating better global quality of life. The outcome compares changes from baseline between patients with type 2 diabetes and patients without diabetes receiving immune checkpoint inhibitor (ICI) therapy.

    Time frame: Baseline, 3 months and 6 months

Secondary outcomes

  1. Change in EQ-5D-5L Index Value

    Health status measured using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L). The index value is derived from the five EQ-5D dimensions using a population value set, where higher values indicate better health status.

    Time frame: Baseline to 3 months and 6 months

  2. Change in EQ-5D-5L Visual Analogue Scale (EQ-VAS) score

    Self-rated health measured using the EQ-5D-5L visual analogue scale (EQ-VAS), where participants rate their health from 0 (worst imaginable health) to 100 (best imaginable health).

    Time frame: Baseline, 3 months and 6 months

  3. Incidence of immune-related diabetes mellitus

    Incidence of immune-related diabetes mellitus within 12 months of ICI initiation (number and proportion). Record occurrence of diabetic ketoacidosis at immune-related diabetes mellitus onset.

    Time frame: Within 12 months after initiation of ICI.

  4. Hospital Admissions

    Number and type of hospital admissions within 6 months of ICI initiation, categorized Immune-related adverse event related, diabetes-related, or other. Derived measures include time to first hospitalization and length of stay.

    Time frame: Within 6 months after initiation of ICI therapy.

  5. Time to Treatment Failure

    Time from first dose of immune checkpoint inhibitor (ICI) therapy to permanent discontinuation of ICI therapy for any reason (including disease progression, toxicity, or other causes) or death, whichever occurs first.

    Time frame: Within 6 months after initiation of immune checkpoint inhibitor therapy

  6. Time to death from any cause (Overall Survival)

    Overall survival defined as time from initiation of ICI therapy to death from any cause.

    Time frame: Within 12 months after initiation of immune checkpoint inhibitor therapy

  7. Association Between Clinical Events and HRQoL Outcomes

    Exploratory analyses examining associations between clinical events (e.g., hospitalizations and immune-related adverse events) and changes in health-related quality of life measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Scores range from 0 to 100, with higher scores indicating better global health status and quality of life.

    Time frame: Baseline to 6 months

  8. Change in Problem Areas in Diabetes Score

    Change in diabetes-related emotional distress measured by the Problem Areas in Diabetes (PAID) questionnaire. The PAID questionnaire assesses diabetes-specific emotional distress, with higher scores indicating greater distress. This outcome is assessed in participants with diabetes.

    Time frame: Baseline to 6 months (assessed at baseline, 3 months, and 6 months)

07

Study locations

3 of 4 sites recruiting
  • Onkologisk afdeling, Klinik Kirurgi og Kræftbehandling
    Aalborg, 9000, Denmark
    Not yet recruiting
    • Maria Skovborg, MD · Contactmaria.skovborg@rn.dk · +45 97661409
    • Maria Skovborg, MD · Principal investigator
  • Kræftafdelingen, Aarhus Universitetshospital
    Aarhus, 8000, Denmark
    Recruiting
  • Afdeling for Kræftbehandling, Herlev Hospital
    Herlev, 2730, Denmark
    Recruiting
  • Sygehus Lillebælt, Onkologisk afdeling Vejle
    Vejle, 7100, Denmark
    Recruiting
    • Julie Stougaard, MD · ContactJulie.Stougaard@rsyd.dk · 2912 3819
    • Julie Stougaard, MD · Principal investigator
08

References and documents

Publications

  • Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365. PubMed 8433390 ↗
  • Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB, Lacouture ME, Masters GA, Naidoo J, Nanni M, Perales MA, Puzanov I, Santomasso BD, Shanbhag SP, Sharma R, Skondra D, Sosman JA, Turner M, Ernstoff MS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021 Jun;9(6):e002435. doi: 10.1136/jitc-2021-002435. PubMed 34172516 ↗
  • Cortellini A, D'Alessio A, Cleary S, Buti S, Bersanelli M, Bordi P, Tonini G, Vincenzi B, Tucci M, Russo A, Pantano F, Russano M, Stucci LS, Sergi MC, Falconi M, Zarzana MA, Santini D, Spagnolo F, Tanda ET, Rastelli F, Giorgi FC, Pergolesi F, Giusti R, Filetti M, Lo Bianco F, Marchetti P, Botticelli A, Gelibter A, Siringo M, Ferrari M, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Ghidini M, Nigro O, Grossi F, De Tursi M, Di Marino P, Queirolo P, Bracarda S, Macrini S, Inno A, Zoratto F, Veltri E, Spoto C, Vitale MG, Cannita K, Gennari A, Morganstein DL, Mallardo D, Nibid L, Sabarese G, Brunetti L, Perrone G, Ascierto PA, Ficorella C, Pinato DJ. Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer. Clin Cancer Res. 2023 Jul 14;29(14):2714-2724. doi: 10.1158/1078-0432.CCR-22-3116. PubMed 37125965 ↗
  • Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015 Apr 9;161(2):205-14. doi: 10.1016/j.cell.2015.03.030. PubMed 25860605 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Oct 2027, 18 months after the start.

Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's planned 18 months is below that.

Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2026
First posted
Mar 12, 2026
StartActual
Mar 18, 2026
Primary completionEst.
Oct 1, 2027
CompletionEst.
Oct 1, 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 22, 2026
Sites
4 sites changed recruiting status (3 now recruiting, 1 now not yet recruiting)
Show 4 sites
  • Onkologisk afdeling, Klinik Kirurgi og Kræftbehandling · Aalborg, Denmarkno status→Not yet recruiting
  • Kræftafdelingen, Aarhus Universitetshospital · Aarhus, Denmarkno status→Recruiting
  • Afdeling for Kræftbehandling, Herlev Hospital · Herlev, Denmarkno status→Recruiting
  • Sygehus Lillebælt, Onkologisk afdeling Vejle · Vejle, Denmarkno status→Recruiting
Oct 22, 2026
Start date
Mar 10, 2026→Mar 18, 2026 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Not yet recruiting→Recruiting
    4 sites changed recruiting status (3 now recruiting, 1 now not yet recruiting)
    Show 4 sites
    • Onkologisk afdeling, Klinik Kirurgi og Kræftbehandling · Aalborg, Denmarkno status→Not yet recruiting
    • Kræftafdelingen, Aarhus Universitetshospital · Aarhus, Denmarkno status→Recruiting
    • Afdeling for Kræftbehandling, Herlev Hospital · Herlev, Denmarkno status→Recruiting
    • Sygehus Lillebælt, Onkologisk afdeling Vejle · Vejle, Denmarkno status→Recruiting
    Start date Mar 10, 2026→Mar 18, 2026 (now actual)
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07466212
Responsible party
Sponsor
First posted
Mar 12, 2026
Start date
Mar 18, 2026
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Debbie Maria Madsen, MD
Contact
debbie.maria.madsen@rsyd.dk
+45 29801558
Christina B Ruhlmann, MD, PhD
study chair · Onkologisk afd R, OUH
Debbie M Madsen, MD
principal investigator · Onkologisk afd R, OUH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion